Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05135325 · ClinicalTrials.gov registry record · NA
Encouraging Blood Donation in Patients With a Blood Type in Short Supply
A NA study, sponsored by Geisinger Clinic.
- Completed
- Registry status
- NA
- Development phase
- 59,093
- Enrollment target
NCT05135325 is a NA study that has completed, run by Geisinger Clinic. The registered enrollment target is 59,093 participants.
The verdict
NCT05135325, a NA study, has completed, sponsored by Geisinger Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 59,093 participants
- Enrollment target
Study Summary
As of November 2021, partly due to the COVID-19 pandemic, there has been a months-long national shortage of several types of blood in the U.S. (O-Pos, O-Neg, A-Neg, B-Neg, and AB-Neg), which has extended to a local blood shortage within the Geisinger community. The broad aim of this collaborative healthcare operations quality improvement project is to determine whether a message indicating that a patient's own blood type is in short supply increases the likelihood that they will donate, compared to a message that mentions a blood shortage without referencing the patient's blood type, or no message at all. Scientists in Geisinger's Behavioral Insights Team (BIT), part of Geisinger's Steele Institute for Health Innovation, will collaborate with Miller Keystone, where Geisinger refers patients who wish to donate blood and from whom Geisinger receives blood for clinical purposes. Patients with one of the needed blood types will be randomized to receive 1) a message about a blood shortage that does not specify the blood types in short supply or their own blood type (no-blood-type message), 2) the same message modified slightly to specify the recipient's blood type, and to mention that their blood type is in short supply (blood-type message), or 3) no message (shortage control group). A second no-contact control group of patients without any of the needed blood types will also be observed (no-shortage control group). Both the blood-type and no-blood-type messages are informed by behavioral science, emphasizing supply needs in local hospitals and providing community-relevant examples of why someone might need blood (e.g., farming or industrial accidents). The BIT will compare how many patients in each group choose to donate blood. They hypothesize that: 1) patients who receive either message will be more likely to donate than patients who receive no message; and 2) patients who receive the blood-type message will be more likely to donate than those who receive the no-blood
Interventions
- BEHAVIORAL Social responsibility
- BEHAVIORAL Patient portal message
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59,093 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2022-06-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05135325
The ClinicalTrials.gov registry entry for NCT05135325 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 59,093 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geisinger Clinic, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Social responsibility is the first listed.
NCT05135325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05135325 about?
NCT05135325 is a clinical study titled "Encouraging Blood Donation in Patients With a Blood Type in Short Supply". As of November 2021, partly due to the COVID-19 pandemic, there has been a months-long national shortage of several types of blood in the U.S. (O-Pos, O-Neg, A-Neg, B-Neg, and AB-Neg), which has extended to a local blood shortage within the Geisinger community. The broad aim of this collaborative he...
What is the current status of trial NCT05135325?
This trial is currently completed. It is a NA study. The enrollment target is 59,093 participants. The study started on 2021-11-15. Estimated completion is 2022-06-06.
What interventions are being tested in trial NCT05135325?
The interventions under investigation include: Social responsibility (BEHAVIORAL), Patient portal message (BEHAVIORAL).
Who is sponsoring clinical trial NCT05135325?
This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.